首页> 美国卫生研究院文献>Toxins >Disruption of the Putative Vascular Leak Peptide Sequence in the Stabilized Ricin Vaccine Candidate RTA1-33/44-198
【2h】

Disruption of the Putative Vascular Leak Peptide Sequence in the Stabilized Ricin Vaccine Candidate RTA1-33/44-198

机译:稳定的蓖麻毒素疫苗候选RTA1-33 / 44-198中假定的血管泄漏肽序列的破坏。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Vitetta and colleagues identified and characterized a putative vascular leak peptide (VLP) consensus sequence in recombinant ricin toxin A-chain (RTA) that contributed to dose-limiting human toxicity when RTA was administered intravenously in large quantities during chemotherapy. We disrupted this potentially toxic site within the more stable RTA1-33/44-198 vaccine immunogen and determined the impact of these mutations on protein stability, structure and protective immunogenicity using an experimental intranasal ricin challenge model in BALB/c mice to determine if the mutations were compatible. Single amino acid substitutions at the positions corresponding with RTA D75 (to A, or N) and V76 (to I, or M) had minor effects on the apparent protein melting temperature of RTA1-33/44-198 but all four variants retained greater apparent stability than the parent RTA. Moreover, each VLP(−) variant tested provided protection comparable with that of RTA1-33/44-198 against supralethal intranasal ricin challenge as judged by animal survival and several biomarkers. To understand better how VLP substitutions and mutations near the VLP site impact epitope structure, we introduced a previously described thermal stabilizing disulfide bond (R48C/T77C) along with the D75N or V76I substitutions in RTA1-33/44-198. The D75N mutation was compatible with the adjacent stabilizing R48C/T77C disulfide bond and the Tm was unaffected, whereas the V76I mutation was less compatible with the adjacent disulfide bond involving C77. A crystal structure of the RTA1-33/44-198 R48C/T77C/D75N variant showed that the structural integrity of the immunogen was largely conserved and that a stable immunogen could be produced from E. coli. We conclude that it is feasible to disrupt the VLP site in RTA1-33/44-198 with little or no impact on apparent protein stability or protective efficacy in mice and such variants can be stabilized further by introduction of a disulfide bond.
机译:Vitetta及其同事在重组蓖麻毒蛋白A链(RTA)中鉴定并表征了假定的血管渗漏肽(VLP)共有序列,当在化疗过程中大量静脉内给予RTA时,这种剂量限制了人类的毒性。我们在更稳定的RTA1-33 / 44-198疫苗免疫原中破坏了这个潜在的毒性位点,并在BALB / c小鼠中使用实验性鼻内蓖麻毒蛋白激发模型确定了这些突变对蛋白质稳定性,结构和保护性免疫原性的影响,以确定是否突变是兼容的。在与RTA D75(至A或N)和V76(至I或M)相对应的位置进行单个氨基酸取代,对RTA1-33 / 44-198的表观蛋白融解温度影响较小,但所有四个变体保留的幅度更大明显比母体RTA稳定。此外,根据动物存活率和几种生物标志物的判断,每种测试的VLP(-)变体提供的抗RAF1-33 / 44-198的抗鼻上鼻内蓖麻毒蛋白攻击的保护作用相当。为了更好地了解VLP位点附近的VLP取代和突变如何影响表位结构,我们引入了先前描述的热稳定二硫键(R48C / T77C)以及RTA1-33 / 44-198中的D75N或V76I取代。 D75N突变与相邻的稳定R48C / T77C二硫键兼容,而Tm不受影响,而V76I突变与与C77相邻的二硫键不兼容。 RTA1-33 / 44-198 R48C / T77C / D75N变体的晶体结构表明,免疫原的结构完整性得到了极大的保护,并且可以从大肠杆菌中产生稳定的免疫原。我们得出结论,破坏RTA1-33 / 44-198中的VLP位点是可行的,而对小鼠中的表观蛋白质稳定性或保护功效几乎没有影响或没有影响,并且可以通过引入二硫键进一步稳定此类变体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号